Holen Sie sich die Stockscreener-App
99.19
2.76%
-2.82
Vorhandelsmarkt:
100.99
1.80
+1.81%
Schlusskurs vom Vortag:
$102.01
Offen:
$102.01
24-Stunden-Volumen:
392.64K
Relative Volume:
0.54
Marktkapitalisierung:
$6.38B
Einnahmen:
$74.06M
Nettoeinkommen (Verlust:
$-114.71M
KGV:
-54.99
EPS:
-1.8039
Netto-Cashflow:
$-117.90M
1W Leistung:
-2.93%
1M Leistung:
-6.03%
6M Leistung:
+16.15%
1J Leistung:
+116.05%
1-Tages-Spanne:
$98.89
$102.42
1-Wochen-Bereich:
$96.69
$104.16
52-Wochen-Spanne:
$45.14
$107.84
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
99.19 | 6.56B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Strong-Buy" at Wolfe Research - MarketBeat
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating - Investing.com India
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating By Investing.com - Investing.com South Africa
Eagle Health Investments LP Takes $5.01 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
HC Wainwright Issues Positive Outlook for PTGX Earnings - MarketBeat
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
A Look At Protagonist Therapeutics (PTGX) Valuation After First Quarter Earnings Swing To Profit - Sahm
Protagonist Therapeutics, Inc. $PTGX Holdings Raised by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Protagonist Therapeutics Strengthens Market Buzz On Nasdaq Composite - Kalkine Media
This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year - simplywall.st
AIHC Capital Management Ltd Buys New Shares in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Behavioral Patterns of PTGX and Institutional Flows - Stock Traders Daily
(SEC Amendment) Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock - Moomoo
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m after option exercise By Investing.com - Investing.com Australia
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m after option exercise - Investing.com UK
PTGX (NASDAQ: PTGX) CEO sells 75K shares under 10b5-1 trading plan - Stock Titan
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $113 - Moomoo
Protagonist Therapeutics Insider Sold Shares Worth $7,509,000, According to a Recent SEC Filing - Moomoo
Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock - Moomoo
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m in shares - Investing.com Nigeria
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m in shares By Investing.com - Investing.com South Africa
Protagonist Therapeutics President, CEO Sold Shares Worth Over $7.5M - TradingView
Protagonist Therapeutics (NASDAQ: PTGX) CEO sells 75,000 shares after exercising options - Stock Titan
75,000-share sale notice filed by PTGX insider (NASDAQ: PTGX) - Stock Titan
State Street Holds 3.12M Protagonist Therapeutics Shares (PTGX) - Stock Titan
Insiders At Protagonist Therapeutics Sold US$11m In Stock, Alluding To Potential Weakness - Moomoo
Protagonist Therapeutics Insider Sold Shares Worth $5,918,880, According to a Recent SEC Filing - Moomoo
Protagonist Therapeutics(PTGX.US) Director Sells US$5.92 Million in Common Stock - Moomoo
Protagonist Therapeutics director Giraudo sells $5.9m in shares By Investing.com - Investing.com Australia
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 36,000 Shares of Stock - MarketBeat
[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity - Stock Titan
Protagonist Therapeutics director Giraudo sells $5.9m in shares - Investing.com
Protagonist Therapeutics Director Sold Shares Worth Over $5.9M - TradingView
BMO reiterates Protagonist Therapeutics stock rating on launch momentum - Investing.com India
BMO reiterates Protagonist Therapeutics stock rating on launch momentum By Investing.com - Investing.com Nigeria
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Protagonist Therapeutics Inc-Aktie (PTGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PATEL DINESH V PH D | President and CEO |
May 12 '26 |
Sale |
100.12 |
75,000 |
7,509,000 |
523,478 |
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):